3 Places The Allergan Tribal Deal May Face Pushback
By Matthew Bultman ( October 12, 2017, 7:14 PM EDT) -- Allergan PLC's controversial attempt to shield patents for dry-eye drug Restasis from review at the Patent Trial and Appeal Board by making a deal with a Native American tribe has drawn intense scrutiny, amid concerns from groups including lawmakers and generic-drug companies. Here are three places where the deal will be closely examined....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.